景峯醫藥(000908.SZ):擬以2.03億元轉讓上海寶山區羅新路50號1-7幢房產
格隆匯9月8日丨景峯醫藥(000908.SZ)公佈,公司為盤活公司資產,提高資產運營及使用效率,綜合交易條件等因素後,擬以2.03億元的價格向上海寶濟藥業有限公司轉讓全資控股子公司上海景峯製藥有限公司坐落於上海市寶山區羅新路50號1-7幢,編號為滬房地寶字(2015)第042185號的《房地產權證》所對應的土地使用權及地上附着建築物所有權。
目標地塊宗地面積為62777平方米,土地使用權面積為62777.10平方米,地上建築物共七幢,地上建築物面積合計為23974.13平方米。
此次出售房產的目的是為了盤活公司資產,提高資產運營及使用效率,符合公司的發展需求。此次交易因交易税費尚不確定,暫時無法準確估算對公司本年業績的具體影響,最終數據將以公司年度經審計的財務數據為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.